Treatment of T-ALL lymphoblasts with the selective CB2 agonist JWH-133 and TRPV1 agonist RTX produces pro-apoptotic and anti-proliferative effects [141]. This evidence concerns the gene CNR2 and acute lymphoblastic leukemia.